A phase III, multicentre, randomized, open-label study of atezolizumab (anti-PD-L1 antibody) plus bevacizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablationR SURGICAL RESECTION OR ABLATION